Attending SCAI next week? Get ready, because Shockwave ain't bringing nothing but heat. Take a look at the hot topics SWAV has in store for you this year including:
Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
Attending SCAI next week? Get ready, because Shockwave ain't bringing nothing but heat. Take a look at the hot topics SWAV has in store for you this year including:
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
A partir de 2 de Maio, a Shockwave Medical está diretamente em Portugal.
Topics: IVL Technology, SWAV News
Desde el 2 de mayo, Shockwave Medical cuenta con un Equipo de Venta Directa en España.
Topics: IVL Technology, SWAV News
After 5 years of innovating together, we’re just getting started! Join us at EuroPCR 2023 to celebrate with us 5 years of Coronary IVL and find out more about our brand-new catheter, Shockwave C2+. We will go through the results of the latest clinical studies in our Symposium and discuss the main features of the new Shockwave C2+ in our Case in Point session.
With the recent acquisition of Neovasc and their innovative Reducer™ device, we are creating new opportunities for patients and physicians in the treatment of refractory angina. Join us at the Tools & Techniques session to learn how we are working to bring these patients relief from their symptoms and hopefully improve their quality of life.
À bientôt à Paris!
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
2022 was another big year for Shockwave and Q4 was no exception! On Twitter, the first Shockwave L6 cases were posted by physicians who participated in its limited release and it was great to see their excitement for our new large-vessel peripheral IVL catheter launching soon in the U.S.! At VIVA ‘22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study; this larger patient data set reinforces the predictability of Shockwave IVL and its ability to consistently modify calcium across vessel beds, challenging lesions and complex patients. Additionally, international calcium experts shared their real-world experiences with the safety and efficacy of coronary IVL across different calcium morphologies, including concentric, eccentric and nodular calcium. Check out that and more in the new PulsePoint Newsletter!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Updated SCAI guidance includes Coronary IVL as a treatment option in all U.S. cath labs regardless of surgical backup status.
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
CMS Corrects Error for IVL Procedures in ASC Setting – Retroactive TPT Payment Eligible for 2022
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Für eine deutschsprachige Version klicken Sie HIER
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
